TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03062319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant
Description: warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant
Description: warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Drug
Description: aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
Study: NCT03413995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Continuous dosing
Study: NCT03907202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily injection of KBP/placebo for up to 28 days
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily injection of KBP/placebo for up to 28 days
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
Study: NCT04255381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
Description: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
Study: NCT02759510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
Study: NCT00963638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MagTabSR
Description: MagTabSR/placebo 168 mgs BID for 6 six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MagTabSR/placebo 168 mgs BID for 6 six weeks
Study: NCT04161482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.
Study: NCT00939185

Intervention type: DRUG
Intervention: Azithromycin
Description: Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
Study: NCT03923088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jacobson's progressive muscle relaxation technique
Description: This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio-visual distraction technique
Description: audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
Study: NCT04414943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Study: NCT02593630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unicirc circumcision
Description: Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
Study: NCT02956473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine MRI
Study: NCT03610282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylphenidate
Description: Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
Study: NCT02956473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy (NAT)
Study: NCT04486443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
Study: NCT02956473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT03100942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 1 x 30 mg tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib
Description: 1 x 30 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 1 x 200 mg tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib
Description: 1 x 200 mg tablet administered orally once daily
Study: NCT03610282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Subjects will received propofol for up to 100 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Subjects will received propofol for up to 100 minutes.
Study: NCT03266731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
Study: NCT04046055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 2 mA
Description: Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation
Description: Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
Study: NCT03041857

Intervention type: RADIATION
Intervention: Observational use of fluoroscopy

Intervention type: RADIATION
Intervention: Observational use of fluoroscopy

Intervention type: RADIATION
Intervention: Observational use of fluoroscopy
Study: NCT00386386

Intervention type: OTHER
Group type: OTHER
Intervention: hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion
Description: Above
Study: NCT01492569

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture therapy
Description: Undergo TAPS at sham point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture therapy
Description: Undergo TAPS
Study: NCT02678273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~.
Study: NCT01253473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium/albuterol
Description: Inhaled ipratropium/albuterol combination 2 puffs four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium/albuterol
Description: Inhaled ipratropium/albuterol combination 2 puffs four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium/albuterol
Description: Inhaled ipratropium/albuterol combination 2 puffs four times daily
Study: NCT01426438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
Study: NCT01784848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Description: Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical treatment
Description: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Study: NCT02956473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard MRI
Study: NCT04347109

Intervention type: DIAGNOSTIC_TEST
Intervention: Non invasive epicardial mapping
Description: Non invasive mapping using Cardio Insight system is performed in all included patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non invasive epicardial mapping
Description: Non invasive mapping using Cardio Insight system is performed in all included patients.
Study: NCT02494115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous drainage
Study: NCT03134209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zipper surgical skin closure
Description: The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl + Dermabond
Description: conventional sutures and skin adhesive glue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyester mesh + Dermabond
Description: conventional sutures and skin adhesive glue
Study: NCT01827020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2 %
Description: 12 mL lidocaine 2% 1mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus Lidocaine
Description: ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 mL saline (0.9% isotonic solution)
Study: NCT03001986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated EV71 vaccine (KMB-17 cells)
Description: Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
Study: NCT04861701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static stretching exercise
Description: The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
Study: NCT03014089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1325
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04523025

Intervention type: DIAGNOSTIC_TEST
Intervention: NLR-ratio
Description: The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation

Intervention type: DIAGNOSTIC_TEST
Intervention: NLR-ratio
Description: The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
Study: NCT01596023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe NIOV Ventilator
Description: Portable, non invasive open ventilation system
Study: NCT02499237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
Study: NCT03328949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVL Coronary Lithotripsy System
Description: The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
Study: NCT01205750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: 450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
Study: NCT02499237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
Study: NCT03091257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Administered Orally once daily
Study: NCT03056469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Completion of patient-reported outcome (PRO) questionnaires
Description: Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Completion of patient-reported outcome (PRO) questionnaires
Description: Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
Study: NCT02445911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study: NCT02985944

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed in adult consecutive patients for different indications

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed in adult consecutive patients for different indications

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed in adult consecutive patients for different indications

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed in adult consecutive patients for different indications
Study: NCT03257657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observation Group participants
Description: Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle group participants
Description: Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
Study: NCT00141011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancrod (Viprinex)
Description: 0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL/kg/hr
Study: NCT01828060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jobelyn™
Description: Sorghum bicolor leaf sheath extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT02126891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tests
Description: Individual parameters of echocardiography and heart rate variability

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tests
Description: Individual parameters of echocardiography and heart rate variability
Study: NCT01657188

Intervention type: DEVICE
Intervention: Cheyne-Stokes respiration by adaptive servoventilation
Study: NCT01163942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Yes/no addition of G-CSF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Yes/no addition of G-CSF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Yes/no addition of G-CSF
Study: NCT01784848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical treatment
Description: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Study: NCT03888586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling Technique
Description: The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
Study: NCT03100942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirabrutinib
Description: 1 x 40 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: 1 x 40 mg tablet administered orally once daily
Study: NCT03888586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Friction Massage Technique
Description: For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
Study: NCT00271024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (drug)
Description: 50 mg q.d. for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (drug)
Description: 50 mg q.d. for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Naltrexone)
Description: Sugar pill manufactured to mimic Naltrexone tablet
Study: NCT01837641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-IV
Description: Administered IV